New drug combination versus standard treatment for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a new drug called telisotuzumab adizutecan, given with bevacizumab, works better than the current standard treatment for colorectal cancer that has spread and stopped responding to previous chemotherapy. The goal is to see if this new combination helps patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with colorectal cancer that has spread to other parts of your body and has stopped responding to previous chemotherapy
- You must be expected to live at least 12 weeks, in your doctor's judgment
- You cannot have previously received drugs that target a protein called c-Met
- You cannot have had severe allergic reactions to bevacizumab or similar drugs
- You must be willing and able to give informed consent and understand the study
- You cannot have had significant drug or alcohol abuse in the past 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
This trial tests a new drug combination (ABT-301, tislelizumab, and bevacizumab) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination can help shrink tumors or slow the disease.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.